DESCRIPTION
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
CATEGORIES
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) , Non-Opioid Analgesics & Antipyretics
CHEMICAL FORMULA
C18H15ClN2O2S
COMPOSITION
Etoricoxib 90 MG
INDICATION
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
PHARMACODYNAMICS
Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.
No Information
ABSORPTION
Bioavailability is 100% following oral administration.
METABOLISM
Hepatic, primarily via CYP3A4.
ELIMINATION
Renal (70%) and fecal (20%)
HALF LIFE
22 hours
TOXICITY
This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
FOOD INTERACTIONS
avoid alcohol
SIDE EFFECTS
Alert your doctor if any of the following symptoms are severe or refuse to go away: – swelling of hands and legs. – rashes. – diarrhoea. – stomach pain. – tiredness.